Teladoc director reports RSU grant and exercise

Teladoc Health director David L. Shedlarz reported equity compensation and an award vesting event.

(Neutral)

Form Type

Rhea-AI Filing Summary

Teladoc Health director David L. Shedlarz reported equity compensation and an award vesting event. On May 21, 2026, he received a grant of 30,441 restricted stock units (RSUs), each representing a right to one share of Teladoc common stock, vesting in full on the earlier of May 21, 2027 or the day before the 2027 annual meeting.

On May 20, 2026, he acquired 29,986 shares of common stock through an exercise or conversion of derivative securities and exercised 28,986 RSUs, fully settling that prior award. Following the stock acquisition, he directly held 61,266 common shares.

Insider Trade Summary

28,986 shares exercised/converted

Exercise 3 txns

Insider SHEDLARZ DAVID L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	30,441	$0.00	$0.00
Exercise	Restricted Stock Units	28,986	$0.00	$0.00
Exercise	Common Stock	29,986	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 30,441 contracts (Direct); Common Stock — 61,266 shares (Direct)

Footnotes (4)

F1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.
F2. On May 22, 2025, the reporting person was granted 28,986 restricted stock units, vesting in full on May 20, 2026.
F3. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.
F4. The restricted stock units vest in full on the earlier of (i) May 21, 2027 and (ii) the day immediately preceding the issuer's 2027 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death.

Key Figures

New RSU grant: 30,441 RSUs New RSU vesting date: May 21, 2027 Common shares acquired: 29,986 shares +3 more

6 metrics

New RSU grant 30,441 RSUs Granted May 21, 2026 to David L. Shedlarz

New RSU vesting date May 21, 2027 Vests on earlier of May 21, 2027 or day before 2027 meeting

Common shares acquired 29,986 shares Common stock acquired via derivative exercise on May 20, 2026

RSUs exercised 28,986 RSUs Previously granted units exercised on May 20, 2026

Common shares held 61,266 shares Direct Teladoc common stock holding after May 20, 2026 transaction

Exercise price $0.00 per unit RSU and stock transactions reported at $0.0000 per share

Key Terms

Restricted Stock Units, contingent right, Change of Control, Deferred Compensation Plan for Non-Employee Directors, +1 more

5 terms

Restricted Stock Units financial

"Restricted stock units convert to shares of TDOC common stock on a one-for-one basis."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each restricted stock unit represents a contingent right to receive one share of TDOC common stock."

Change of Control financial

"immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors)"

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

Deferred Compensation Plan for Non-Employee Directors financial

"Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors)"

separation of service financial

"within 90 days following the date that is 30 days following the reporting person's separation of service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Teladoc (TDOC) director David L. Shedlarz report in this Form 4?

He reported equity compensation activity, not open-market trades. The filing shows a new grant of restricted stock units and the exercise of previously granted units into common shares, updating his direct stock and RSU holdings in Teladoc Health.

How many Teladoc (TDOC) restricted stock units were granted to David L. Shedlarz?

He was granted 30,441 restricted stock units. Each unit represents a contingent right to receive one share of Teladoc common stock. This award is part of his director compensation and is subject to vesting conditions detailed in the filing’s footnotes.

When do David L. Shedlarz’s new Teladoc (TDOC) RSUs vest?

The new RSUs vest in full on the earlier of May 21, 2027 or the day immediately preceding Teladoc’s 2027 annual meeting of stockholders. Actual share delivery then follows specific timing triggers, including separation of service, a qualifying change of control, or death.

How many Teladoc (TDOC) common shares does David L. Shedlarz hold after these transactions?

After the May 20, 2026 stock acquisition, he directly holds 61,266 shares of Teladoc common stock. This reflects the reported exercise or conversion transaction and provides updated information on his direct equity stake in the company.

What prior Teladoc (TDOC) RSU award did David L. Shedlarz exercise?

He exercised 28,986 restricted stock units that were granted on May 22, 2025 and vested in full on May 20, 2026. Each unit converted into one share of Teladoc common stock, and the RSU balance for that award fell to zero after settlement.

Are David L. Shedlarz’s Teladoc (TDOC) transactions open-market buys or sales?

No open-market buys or sales are reported. The Form 4 shows a grant of restricted stock units and exercises or conversions of derivative awards into common stock. These are compensation-related and do not reflect discretionary open-market trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 05/21/2026 - 05:13 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SHEDLARZ DAVID L

(Last)

(First)

(Middle)

C/O TELADOC HEALTH, INC.,

155 E 44TH ST, FLOOR 17

(Street)

NEW YORK

10017

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Teladoc Health, Inc. [ TDOC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/20/2026		M		29,986	A	⁽¹⁾	61,266	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	05/20/2026		M			28,986	⁽²⁾	⁽²⁾	Common Stock	28,986	$0	0	D
Restricted Stock Units	⁽³⁾	05/21/2026		A		30,441		⁽⁴⁾	⁽⁴⁾	Common Stock	30,441	$0	30,441	D

Explanation of Responses:

1. Restricted stock units convert to shares of TDOC common stock on a one-for-one basis.

2. On May 22, 2025, the reporting person was granted 28,986 restricted stock units, vesting in full on May 20, 2026.

3. Each restricted stock unit represents a contingent right to receive one share of TDOC common stock.

4. The restricted stock units vest in full on the earlier of (i) May 21, 2027 and (ii) the day immediately preceding the issuer's 2027 annual meeting of stockholders. Vested shares will be delivered to the reporting person on the earliest to occur of (i) within 90 days following the date that is 30 days following the reporting person's separation of service, (ii) immediately prior to, on or within 30 days following a Change of Control (as defined in the issuer's Deferred Compensation Plan for Non-Employee Directors) and (iii) the reporting person's death.

Remarks:

	/s/ Adam C. Vandervoort, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

Teladoc director reports RSU grant and exercise

Rhea-AI Filing Summary

Positive

Negative